LOVE Cannara Biotech Inc.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Cannara Biotech (TSE: LOVE)
›
Cannara Biotech (TSE: LOVE) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 452 employees.
The shares were at 2.020 CAD on 19 November 2026, up 26.3% over 52 weeks. Its 52-week range is 1.550 CAD to 2.370 CAD: the price is 14.8% below the high and 30.3% above the low.
At a market capitalisation of 199.54M CAD, it trades at 18.4 times trailing earnings and 9.9 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 26% for LOVE.
Cannara Biotech reports return on equity of 12.8%, an operating margin of 15.6% and revenue up 16.4% year over year.
Its debt exceeds its cash by 15.19M CAD, a debt-to-equity ratio of 0.41. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 4 analysts cover the stock; their mean price target of 3.375 CAD is 67.1% above the current price. The next earnings report is expected on 23 November 2026.